Skip to main content
Year archive

ARIX BIOSCIENCE PLC — 2023 filings

All 50 regulatory filings released by ARIX BIOSCIENCE PLC (ARIX) in 2023, sourced directly from the official regulator.

50 Filings
2023 Period
2023 filings (50)
Filing Released Lang
Update regarding timing of Proposed Scheme of Reconstruction
Delisting Announcement
2023-12-22 English
Unaudited NAV for November 2023
Net Asset Value
2023-12-13 English
Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial
Regulatory Filings
2023-12-08 English
Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Share Issue/Capital Change
2023-11-13 English
Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Share Issue/Capital Change
2023-11-10 English
PDMR Notification & Director Shareholding
Director's Dealing
2023-11-10 English
Unaudited NAV for October 2023
Net Asset Value
2023-11-08 English
PDMR Notification & Director Shareholding
Director's Dealing
2023-11-03 English
PDMR Notification & Director Shareholding
Director's Dealing
2023-11-02 English
Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
Regulatory Filings
2023-11-01 English
Portfolio company Harpoon Therapeutics announces up to $150 million private placement
Share Issue/Capital Change
2023-10-24 English
Unaudited NAV for September 2023
Net Asset Value
2023-10-06 English
Interim Results for the Six Months Ended 30 June 2023
Interim / Quarterly Report H1 2023
2023-09-27 English
Board Change
Board/Management Information
2023-09-27 English
Notice of Results and Investor Presentation
Report Publication Announcement
2023-09-14 English
Unaudited NAV for August 2023
Net Asset Value
2023-09-14 English
Unaudited NAV for July 2023
Net Asset Value
2023-08-07 English
Holding(s) in Company
Major Shareholding Notification
2023-07-17 English
Arix Announces Strategic Review
Management Reports
2023-07-13 English
Unaudited NAV for June 2023
Net Asset Value
2023-07-13 English
Portfolio company Disc Medicine raises $157.8 million in public offering
Share Issue/Capital Change
2023-06-23 English
Portfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA
Legal Proceedings Report
2023-06-09 English
Unaudited NAV for May 2023
Net Asset Value
2023-06-09 English
Director/PDMR Shareholding
Director's Dealing
2023-05-31 English
Results of Annual General Meeting - Special Business
AGM Information
2023-05-24 English
Correction: Result of Annual General Meeting
Declaration of Voting Results & Voting Rights Announcements
2023-05-24 English
Result of Annual General Meeting
AGM Information
2023-05-23 English
Portfolio company Ensoma announces closing of Series B Extension
Share Issue/Capital Change
2023-05-16 English
Unaudited NAV for April 2023
Net Asset Value
2023-05-12 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements
2023-05-05 English
Director/PDMR Shareholding
Director's Dealing
2023-05-04 English
Director/PDMR Shareholding
Director's Dealing
2023-05-04 English
Director/PDMR Shareholding
Director's Dealing
2023-05-02 English
Arix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune
Share Issue/Capital Change
2023-04-27 English
Arix Bioscience Plc - Annual Report & Accounts to 31 December 2022 - ESEF
Annual Report (ESEF) FY 2022
2023-04-26 English
Arix Bioscience Plc - Proxy form for AGM 2023
Proxy Solicitation & Information Statement
2023-04-25 English
Arix Bioscience Plc - Notice of Annual General Meeting 2023
AGM Information
2023-04-25 English
Arix Bioscience Plc - Annual Report & Accounts to 31 December 2022
Annual Report FY 2022
2023-04-25 English
Financial Results for the Year Ended 31 December 2022, Publication of Annual Report & Notice of AGM
Report Publication Announcement FY 2022
2023-04-25 English
Full Year results now to be released on 25 April 2023
Report Publication Announcement
2023-04-19 English
Unaudited NAV for March 2023
Net Asset Value
2023-04-17 English
Notice of Results and Investor Presentation
Report Publication Announcement
2023-04-14 English
Portfolio company Harpoon Therapeutics announces closing of $25 million private placement
Share Issue/Capital Change
2023-03-28 English
Unaudited NAV for February 2023
Net Asset Value
2023-03-16 English
Portfolio company Disc Medicine announces $62.5 million financing
Share Issue/Capital Change
2023-02-14 English
Director/PDMR Shareholding
Director's Dealing
2023-02-06 English
Unaudited NAV for January 2023
Net Asset Value
2023-02-06 English
Unaudited NAV for December 2022
Net Asset Value
2023-01-30 English
Board Change
Board/Management Information
2023-01-26 English
Portfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
Regulatory Filings
2023-01-05 English